Friday - March 29, 2024
'Non-Small Cell Lung Cancer Drugs Market Worth $9.37bn in 2021' Says Visiongain Report
August 16, 2018
LONDON, England, Aug. 16 -- Visiongain, a independent media company, issued the following news release:

Visiongain's new report Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027 (https://www.visiongain.com/report/non-small-cell-lung-cancer-nsclc-drugs-market-forecast-2017-2027/): Chemotherapy, EGFR and ALK Inhibitors, VEGF/VEGFR Inhibitors, Immunotherapy, Other indicates that the non-small cell lung cancer drugs market will see $9.37bn in spending in 2021.

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation
Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products